# Celecoxib in Treating Patients With Bladder Cancer

> **NCT00006124** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 152 (estimated)

## Conditions studied

- Recurrent Bladder Cancer

## Interventions

- **DRUG:** celecoxib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00006124
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2006-03
- **Final completion:** 2008-04
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2013-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006124, "Celecoxib in Treating Patients With Bladder Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00006124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*